Elad Kedar's guest appearances

Elad Kedar

OIS Podcast

Empowered Patient Podcast

The Optical Journal Podcast

Patrik De Haes

Joel Wishkovsky

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Jay Cormier

Robin Zander

Andrew Newberg

Mike Rea

OwlTail

Jeff Weinhuff

Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in preparation of their phase 3 of CSF-1 drops for temporary correction of presbyopia. Jeff Weinhuff from Visionary Ventures joins the conversation as Chairman of the Board to explain how he evaluated the Orasis technology and what VCs look for.

Elad Kedar and Jeff Weinhuff Share the Recipe for Orasis Pharmaceuticals

Elad Kedar, CEO, Orasis discusses CSF-1, the company's corrective eye drop being developed for the treatment of presbyopia as an alternative to reading glasses.  Presbyopia, the inability to focus on near objects, is common after the age of 40 and affects more than 1.8 billion people worldwide.  While glasses have been used for hundreds of years to correct vision, ophthalmologists are excited about these innovative eye drops that will change eye care. Orasis-Pharma.com 

<p>Elad Kedar, CEO, Orasis discusses CSF-1, the company's corrective eye drop being developed for the treatment of presbyopia as an alternative to reading glasses.  Presbyopia, the inability to focus on near objects, is common after the age of 40 and affects more than 1.8 billion people worldwide.  While glasses have been used for hundreds of years to correct vision, ophthalmologists are excited about these innovative eye drops that will change eye care.</p> <p><a href="http://orasis-pharma.com" rel="noopener nofollow" target="_blank">Orasis-Pharma.com</a> </p>

Advances in Treatment of Presbyopia with Elad Kedar Orasis Pharmaceuticals